SWOT Analysis
- S
- W
- O
- T
-
Strength (5)
Stocks with MACD Crossover Above
-
Weakness (4)
See all stocks where promoters decreased their stake. Promoters decreasing their shareholding in a stock is considered negative for the stock.
-
Opportunity (1)
FII / FPI or Institutions increasing their shareholding
-
Threats (1)
See all stocks where MFs decreased their stake last quarter. MFs decreasing their shareholding in a stock is considered negative for the stock.
- MACD Crossover Above Signal Line
- Strong Momentum: Price above short, medium and long term moving averages
- Companies with Low Debt
- Book Value per share Improving for last 2 years
- RSI indicating price strength
- FII / FPI or Institutions increasing their shareholding
Technical Analysis
Moving Averages
- 5 Day 428.6
- 10 Day 427.1
- 12 Day 426.5
- 20 Day 424.3
- 26 Day 422.6
- 50 Day 415.3
- 100 Day 405.2
- 200 Day 405.3
Current Price
- Bullish Moving Averages 16
- Bearish Moving Averages 0
Resistance and support
- First Resistance 436.0
- Second Resistance 440.2
- Third Resistance 445.2
- First Support 426.8
- Second Support 421.8
- Third Support 417.6
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 8.46%
- 5.65%
- 9.39%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 2,260.39 | 2,173.65 | 2,266.91 | 2,497.97 | 2,251.17 |
|
| Operating Profit | 262.50 | 265.17 | 269.18 | 286.05 | 321.17 |
|
| OP Profit Margin | 11.61 | 12.20 | 11.87 | 11.45 | 14.27 |
|
| Interest | 28.14 | 32.20 | 33.21 | 36.18 | 23.05 |
|
| Profit After Tax | 169.22 | 157.31 | 141.88 | 152.81 | 195.00 |
|
| Cash Profit | 228.52 | 208.53 | 191.31 | 200.10 | 242.39 |
|
| EPS | 18.54 | 17.24 | 15.43 | 16.50 | 21.06 |
|
- CAGR IN 10 YEARS
- 15.40%
- -0.69%
- 8.10%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 91.27 | 91.27 | 91.94 | 92.60 | 92.60 |
|
| Reserve Surplus | 1,313.52 | 1,160.08 | 1,083.27 | 1,021.70 | 879.57 |
|
| TOT Debts | 420.97 | 515.57 | 474.72 | 535.48 | 519.36 |
|
| Gross Block | 1,623.74 | 1,359.59 | 1,276.97 | 1,141.55 | 1,112.47 |
|
| Capital Work In Progress | 106.20 | 273.40 | 221.62 | 160.75 | 59.62 |
|
| Cash Liquid Investment | 4.70 | 4.57 | 3.82 | 2.68 | 2.21 |
|
| Net Working Capital | 660.46 | 678.29 | 662.24 | 806.96 | 747.62 |
|
| Current Assets | 1,214.24 | 1,181.90 | 1,182.04 | 1,349.53 | 1,273.19 |
|
| Current Liabilities | 553.78 | 503.61 | 519.81 | 542.57 | 525.57 |
|
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
Mar 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 631.68 | 528.80 | 578.95 | 520.96 | 622.96 |
|
| Gross Profit | 73.52 | 36.58 | 69.33 | 57.52 | 82.88 |
|
| Gross Profit Margins | 36.79 | 41.90 | 37.56 | 35.92 | 43.80 |
|
| Operating Profit | 79.28 | 42.31 | 75.19 | 63.95 | 88.65 |
|
| OP Profit Margin | 10.32 | 5.42 | 10.67 | 10.00 | 12.54 |
|
| Interest | 6.59 | 6.95 | 6.01 | 6.82 | 7.48 |
|
| Profit After Tax | 44.96 | 33.84 | 41.78 | 48.64 | 61.48 |
|
| Cash Profit | 59.91 | 48.71 | 55.33 | 60.91 | 73.69 |
|
| EPS | 4.93 | 3.71 | 4.58 | 5.33 | 6.74 |
|
- CAGR IN 10 YEARS
- 15.40%
- -0.69%
- 8.10%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 17.23 | 19.71 | 28.11 | 20.47 | 20.37 |
|
| P/BV | 2.08 | 2.48 | 3.39 | 2.81 | 4.09 |
|
| MCAP Sales | 1.29 | 1.43 | 1.76 | 1.25 | 1.76 |
|
| Asset Turnover | 1.26 | 1.27 | 1.37 | 1.58 | 1.65 |
|
| EV/EBITDA | 12.57 | 12.96 | 16.31 | 12.70 | 13.77 |
|
| DEBT/EQUITY | 0.35 | 0.41 | 0.44 | 0.51 | 0.47 |
|
| ROE | 12.74 | 12.97 | 12.39 | 14.65 | 21.29 |
|
| ROCE | 11.64 | 13.49 | 13.65 | 15.24 | 20.38 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Aarti Drugs Ltd.
Pharmaceuticals company Aarti Drugs announced Q1FY27 results
Consolidated Financial Highlights:
- The Revenue from Operations for the Company in Q1FY27 stood at Rs 70,278 lakh, showing a YoY growth of 19.01% from Rs 59,051 lakh in Q1FY26 and a QoQ decline of 2.43% from Rs 72,030 lakh in Q4FY26.
- The Total Income reached Rs 70,359 lakh in Q1FY27, up 19.09% YoY from Rs 59,082 lakh in Q1FY26, while declining 2.42% QoQ from Rs 72,106 lakh in Q4FY26.
- Profit before exceptional items and tax for Q1FY27 was Rs 7,132 lakh, marking a YoY increase of 39.54% compared to Rs 5,111 lakh in Q1FY26 and a QoQ growth of 1.36% from Rs 7,036 lakh in Q4FY26.
- The Profit before tax (PBT) after exceptional items was reported at Rs 6,924 lakh for Q1FY27, representing a YoY growth of 35.47% from Rs 5,111 lakh in Q1FY26 and a QoQ decline of 1.59% from Rs 7,036 lakh in Q4FY26.
- Net Profit (attributable to owners of the Company) for Q1FY27 was Rs 5,017 lakh, showcasing a YoY decrease of 6.94% from Rs 5,391 lakh in Q1FY26 and a QoQ decline of 9.10% from Rs 5,519 lakh in Q4FY26. (Note: Q1FY26 included a tax reversal for earlier years amounting to Rs 1,489 lakh).
- Total Comprehensive Income for Q1FY27 stood at Rs 5,019 lakh, down 7.19% YoY from Rs 5,408 lakh in Q1FY26 and 13.51% QoQ from Rs 5,803 lakh in Q4FY26.
- The Basic and Diluted Earnings Per Share (EPS) for Q1FY27 was reported at Rs 5.49, compared to Rs 5.91 in Q1FY26 and Rs 6.05 in Q4FY26.
Standalone Financial Highlights:
- Revenue from Operations for Q1FY27 was Rs 62,745 lakh, up 20.44% YoY from Rs 52,096 lakh in Q1FY26, while recording a slight QoQ decrease of 0.67% from Rs 63,168 lakh in Q4FY26.
- Total Income for the quarter stood at Rs 62,765 lakh, representing a YoY growth of 20.39% from Rs 52,135 lakh in Q1FY26 and a QoQ decline of 0.77% from Rs 63,251 lakh in Q4FY26.
- Profit before exceptional items and tax for Q1FY27 reached Rs 6,994 lakh, representing a YoY growth of 54.56% from Rs 4,525 lakh in Q1FY26 and a QoQ increase of 19.43% from Rs 5,856 lakh in Q4FY26.
- The Profit before tax (PBT) for Q1FY27 was Rs 6,785 lakh, marking a YoY growth of 49.94% from Rs 4,525 lakh in Q1FY26 and a QoQ increase of 15.86% from Rs 5,856 lakh in Q4FY26.
- Net Profit for the period was reported at Rs 5,085 lakh in Q1FY27, up 4.54% YoY from Rs 4,864 lakh in Q1FY26 and up 13.10% QoQ from Rs 4,496 lakh in Q4FY26.
- The Standalone Basic and Diluted EPS for Q1FY27 stood at Rs 5.57, compared to Rs 5.33 in Q1FY26 and Rs 4.93 in Q4FY26.
Business Highlights:
- Exceptional Items: During Q1FY27, the Company reported an exceptional item of Rs 209 lakh (Rs 2.09 crore) representing the write-off of Capital Work-in-Progress (CWIP).
- Subsidiary Structure: As of June 30, 2026, the Company has three subsidiaries: Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SpA, along with two step-down subsidiaries: Pharma Go SpA and Tripharma Chile SpA.
- Expansion Status: The Company is engaged in routine expansion plans as evidenced by the details regarding the administrative building at E1.
Adhish Patil, CFO & COO, Aarti Drugs, said: “We began FY27 with a strong operational and financial performance, driven by a mix of volume growth and improved realizations across our API & Speciality Chemicals portfolio and disciplined execution. The quarter marked a recovery in the pricing environment compared to the previous year, while our continued focus on operational efficiencies and product mix supported profitability. Despite an uncertain and volatile global environment, Aarti Drugs delivered a robust quarter as production across our facilities continued without disruption, reflecting the resilience of our business model.
EBITDA increased by 30% YoY to Rs 96.9 crore, and EBITDA margins expanded by 120 basis points to 13.8%. Product mix optimization and operational efficiencies strengthened profitability.
The demand outlook for our product portfolio looks encouraging. The company's USFDA and UK approvals for facilities remain important growth drivers, supporting expansion in regulated markets.
Sayakha continued its planned ramp-up during the quarter, operating at nearly 65% utilization and progressively contributing to our backward integration capabilities. We are also expanding our oral solid dosage (OSD) capabilities through brownfield and adjacent plot developments in Baddi, Himachal Pradesh which is expected to double our production capacity.
Operationally, we remain focused on improving capacity utilization, optimizing product mix and enhancing manufacturing efficiencies across our facilities. These initiatives, together with the continued ramp-up of Sayakha, are expected to progressively improve operating leverage and strengthen margin performance over the medium term.
Looking ahead, global demand continues to remain resilient, and we aim to enhance ourselves on the regulatory-compliance front to continue to capitalize on opportunities. Alongside this, investments in process optimization, capacity enhancement, backward integration, and operational efficiencies remain a focus.”
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Aarti Drugs Ltd | 431.80 | 3,941.04 | -16.20 | 0.09 | 20.62 | Mar 2026 |
| Dynachem Pharmaceuticals (Export) Ltd | 0.00 | 0.00 | - | - | - | Mar 2011 |
| Rubicon Research Ltd | 1,751.10 | 28,986.29 | 178.75 | 0.13 | 100.74 | Mar 2026 |
| Corona Remedies Ltd | 2,201.80 | 13,466.23 | 53.07 | 0.07 | 67.57 | Mar 2026 |
| Akums Drugs & Pharmaceuticals Ltd | 783.70 | 12,334.97 | 66.25 | 0.10 | 42.15 | Mar 2026 |
| Sanofi Consumer Healthcare India Ltd | 4,033.40 | 9,289.17 | -23.43 | 0.06 | 34.77 | Dec 2025 |
| Entero Healthcare Solutions Ltd | 1,732.30 | 7,539.50 | 52.99 | 0.15 | 44.99 | Mar 2026 |
| Supriya Lifescience Ltd | 906.30 | 7,294.16 | 36.83 | 0.16 | 36.73 | Mar 2026 |
| Symbiotec Pharmalab Ltd | 1,095.10 | 7,036.69 | -0.24 | - | 63.93 | Mar 2026 |
| Innova Captab Ltd | 1,179.80 | 6,751.40 | 36.57 | - | 43.86 | Mar 2026 |
| Morepen Laboratories Ltd | 120.90 | 6,624.76 | 124.89 | 0.29 | 47.04 | Mar 2026 |
| Sun Pharma Advanced Research Company Ltd | 193.92 | 6,293.12 | 34.39 | 0.17 | 3.97 | Mar 2026 |
| IOL Chemicals & Pharmaceuticals Ltd | 203.15 | 5,963.01 | 75.07 | 0.17 | 35.42 | Mar 2026 |
| Orchid Pharma Ltd | 989.70 | 5,926.84 | 38.33 | 0.16 | 552.57 | Mar 2026 |
| FDC Ltd | 352.50 | 5,739.06 | -24.98 | 0.09 | 19.64 | Mar 2026 |
| Gujarat Themis Biosyn Ltd | 427.40 | 5,562.68 | 10.85 | 0.23 | 119.12 | Mar 2026 |
| Novartis India Ltd | 2,046.80 | 5,053.71 | 105.62 | - | 51.96 | Mar 2026 |
| RPG Life Sciences Ltd | 2,802.40 | 4,634.89 | 16.80 | 0.11 | 38.78 | Mar 2026 |
| Gufic BioSciences Ltd | 436.00 | 4,372.32 | 23.16 | 0.10 | 59.51 | Mar 2026 |
| SMS Pharmaceuticals Ltd | 442.95 | 4,148.32 | 55.56 | 0.10 | 40.53 | Mar 2025 |
| Unichem Laboratories Ltd | 545.70 | 3,842.04 | 7.74 | 0.17 | 12.60 | Mar 2026 |
| Kwality Pharmaceuticals Ltd | 3,471.20 | 3,601.79 | 108.78 | 0.22 | 44.49 | Mar 2026 |
| Solara Active Pharma Sciences Ltd | 742.05 | 3,601.33 | 9.28 | 0.12 | -2244.85 | Mar 2026 |
| Ind-Swift Laboratories Ltd | 373.25 | 3,245.84 | 254.23 | 0.21 | 56.62 | Mar 2025 |
| Advanced Enzyme Technologies Ltd | 287.80 | 3,222.67 | -15.37 | 0.13 | 18.78 | Mar 2026 |
| Hikal Ltd | 226.04 | 2,787.09 | -16.22 | 0.14 | -82.52 | Mar 2026 |
| Dishman Carbogen Amcis Ltd | 170.52 | 2,673.47 | -38.69 | 0.18 | 165.49 | Mar 2026 |
| Shukra Pharmaceuticals Ltd | 55.93 | 2,465.32 | 35.03 | - | 72.68 | Mar 2025 |
| Indoco Remedies Ltd | 249.01 | 2,298.45 | -16.94 | 0.13 | 733.38 | Mar 2026 |
| Windlas Biotech Ltd | 1,109.45 | 2,289.49 | 14.02 | - | 34.38 | Mar 2026 |
| Sai Parenterals Ltd | 510.75 | 2,256.45 | 25.89 | - | 108.71 | Mar 2026 |
| Panacea Biotec Ltd | 367.90 | 2,253.41 | -19.92 | 0.17 | -252.05 | Mar 2026 |
| Fredun Pharmaceuticals Ltd | 1,303.50 | 2,155.74 | -11.57 | - | 49.28 | Mar 2026 |
| Syncom Formulations (India) Ltd | 20.04 | 1,883.76 | 11.33 | 0.19 | 22.00 | Mar 2026 |
| Hester Biosciences Ltd | 2,195.60 | 1,867.77 | 7.01 | 0.15 | 13.59 | Mar 2026 |
| NGL Fine Chem Ltd | 2,768.20 | 1,710.75 | 104.57 | 0.16 | 30.01 | Mar 2026 |
| Jagsonpal Pharmaceuticals Ltd | 228.42 | 1,506.60 | -6.02 | 0.09 | 33.09 | Mar 2026 |
| Amrutanjan Health Care Ltd | 493.80 | 1,427.61 | -35.45 | 0.08 | 26.44 | Mar 2026 |
| Fermenta Biotech Ltd | 474.15 | 1,395.47 | 48.92 | 0.21 | 24.06 | Mar 2026 |
| Kopran Ltd | 277.60 | 1,341.53 | 57.31 | 0.21 | 53.72 | Mar 2026 |
| Anlon Healthcare Ltd | 22.90 | 1,217.17 | 77.38 | 0.15 | 35.84 | Mar 2026 |
| Lincoln Pharmaceuticals Ltd | 604.85 | 1,211.50 | 8.87 | 0.13 | 12.59 | Mar 2025 |
| Themis Medicare Ltd | 123.97 | 1,141.77 | 0.31 | 0.22 | 28.76 | Mar 2026 |
| Sigachi Industries Ltd | 29.60 | 1,131.07 | -33.30 | 0.19 | 42.87 | Mar 2026 |
| Bajaj Healthcare Ltd | 330.55 | 1,112.72 | -23.73 | 0.10 | 62.80 | Mar 2026 |
| Bharat Parenterals Ltd | 1,509.70 | 1,040.48 | 15.51 | - | -34.56 | Mar 2026 |
| Anuh Pharma Ltd | 93.48 | 936.89 | 7.07 | 0.10 | 21.18 | Mar 2026 |
| Shree Ganesh Remedies Ltd | 697.75 | 895.74 | 29.93 | - | 58.09 | Mar 2026 |
| Wanbury Ltd | 222.75 | 778.89 | -12.51 | 0.14 | 13.96 | Mar 2026 |
| Zim Laboratories Ltd | 135.51 | 727.13 | 79.46 | 0.16 | 196.09 | Mar 2026 |
| Albert David Ltd | 833.60 | 475.99 | 3.88 | 0.13 | 21.44 | Mar 2026 |
| Haleos Labs Limited | 1,497.60 | 452.77 | 23.45 | - | 29.33 | Mar 2025 |
| Medicamen Biotech Ltd | 328.05 | 444.93 | -3.81 | - | 44.63 | Mar 2026 |
| Jenburkt Pharmaceuticals Ltd | 979.90 | 432.46 | -6.24 | - | 13.15 | Mar 2026 |
| Aarey Drugs & Pharmaceuticals Ltd | 102.13 | 315.32 | 44.48 | - | 75.92 | Mar 2025 |
| Medico Remedies Ltd | 34.89 | 289.53 | -10.38 | 0.19 | 21.09 | Mar 2026 |
| Nectar Lifescience Ltd | 10.98 | 213.30 | -34.05 | 0.18 | -0.87 | Mar 2026 |
| Brooks Laboratories Ltd | 61.53 | 181.25 | -60.23 | 0.24 | 13.67 | Mar 2026 |
| Bal Pharma Ltd | 100.67 | 160.28 | 12.24 | 0.14 | 22.04 | Mar 2025 |
| Parnax Lab Ltd | 128.20 | 147.25 | 7.15 | - | 16.08 | Mar 2025 |
| Alpa Laboratories Ltd | 59.35 | 124.88 | -37.12 | 0.17 | 31.11 | Mar 2025 |
| Krebs Biochemicals & Industries Ltd | 57.31 | 123.56 | -28.22 | 0.19 | -8.74 | Mar 2025 |
| Makers Laboratories Ltd | 190.88 | 112.63 | 25.09 | - | 10.08 | Mar 2026 |
| Vineet Laboratories Ltd | 36.78 | 70.64 | 23.46 | - | 62.84 | Mar 2025 |
| Mangalam Drugs and Organics Ltd | 34.26 | 54.23 | -54.40 | 0.21 | -1.42 | Mar 2025 |
| Biofil Chemicals & Pharmaceuticals Ltd | 32.83 | 53.41 | -24.49 | 0.13 | 109.53 | Mar 2026 |
| Vivo Bio Tech Ltd | 16.77 | 37.21 | -14.79 | - | -12.95 | Mar 2025 |
| Ortin Global Ltd | 15.83 | 12.87 | 29.75 | 0.16 | -14.40 | Mar 2025 |
| Rajnish Wellness Ltd | 0.40 | 0.00 | -59.60 | - | -8.00 | Mar 2026 |
| Bharat Immunological & Biological Corporation Ltd | 14.16 | 0.00 | -35.72 | - | -3.39 | Mar 2023 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Aarti Drugs Limited - Copy of Newspaper Publication
Sep 03, 2026Aarti Drugs Limited has informed the Exchange about Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 03, 2026Newspaper Publication
Reg. 34 (1) Annual Report.
Sep 02, 2026Please find attached Annual Report for FY 2025-26
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 01, 2026Newspaper Publication
Board Meeting for Today
Aug 27, 2026Employees Stock Option Plan
Board Meeting Outcome for Approval Of Aarti Drugs Limited Performance Stock Option Plan 2026
Aug 27, 2026approval of Aarti Drugs Limited Performance Stock Option Plan 2026
Aarti Drugs Limited - Outcome of Board Meeting
Aug 27, 2026Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026.
Board Meeting Intimation for Aarti Drugs Limited - Performance Stock Option Plan 2026
Aug 24, 2026Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/08/2026 inter alia to consider and approve Aarti Drugs Limited - Performance Stock Option Plan 2026
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-08-27 | Employees Stock Option Plan | |
| 2026-07-31 | Quarterly Results | |
| 2026-05-15 | Audited Results | |
| 2026-02-03 | Quarterly Results & Interim Dividend | |
| 2025-11-07 | Quarterly Results | |
| 2025-07-18 | Quarterly Results | |
| 2025-05-06 | Audited Results | |
| 2025-01-29 | Quarterly Results & Interim Dividend | |
| 2024-10-24 | Quarterly Results | |
| 2024-08-26 | Buy Back of Shares | |
| 2024-07-26 | Quarterly Results | |
| 2024-05-03 | Audited Results | |
| 2024-01-24 | Quarterly Results & Interim Dividend | |
| 2023-10-19 | Quarterly Results | |
| 2023-07-21 | Quarterly Results & Buy Back | |
| 2023-04-29 | Audited Results | |
| 2023-01-27 | Quarterly Results & Interim Dividend | |
| 2022-10-20 | Quarterly Results | |
| 2022-07-27 | Quarterly Results | |
| 2022-05-09 | Audited Results | |
| 2022-01-31 | Audited Results & Interim Dividend | |
| 2021-10-27 | Quarterly Results | |
| 2021-07-27 | Quarterly Results | |
| 2021-05-15 | Audited Results | |
| 2021-03-19 | Buy Back of Shares | |
| 2021-01-25 | Quarterly Results | |
| 2020-10-23 | Audited Results | |
| 2020-10-20 | Audited Results & Interim Dividend | |
| 2020-08-20 | Bonus issue | |
| 2020-07-25 | Quarterly Results | |
| 2020-05-15 | Audited Results | |
| 2020-02-06 | Quarterly Results & Interim Dividend | |
| 2019-10-23 | Audited Results | |
| 2019-07-26 | Quarterly Results | |
| 2019-05-15 | Audited Results & Final Dividend | |
| 2019-03-15 | Buy Back of Shares | |
| 2019-02-11 | Quarterly Results | |
| 2018-11-02 | Quarterly Results | |
| 2018-08-13 | Quarterly Results | |
| 2018-05-16 | Audited Results & Final Dividend | |
| 2018-02-13 | Quarterly Results | |
| 2018-01-08 | Buy Back of Shares | |
| 2017-11-13 | Quarterly Results | |
| 2017-08-18 | Quarterly Results | |
| 2017-05-23 | Audited Results & Final Dividend | |
| 2017-02-08 | Quarterly Results | |
| 2016-11-09 | Quarterly Results | |
| 2016-10-17 | Buy Back of Shares | |
| 2016-08-12 | Quarterly Results | |
| 2016-05-05 | Audited Results | |
| 2016-03-16 | 3rd Interim Dividend | |
| 2016-02-05 | Quarterly Results & 2nd Interim Dividend | |
| 2015-11-06 | Quarterly Results & Interim Dividend | |
| 2015-07-31 | Quarterly Results | |
| 2015-05-20 | Audited Results & Final Dividend | |
| 2015-03-26 | Others | To consider & approve the allotment of 121,08,550 Equity shares as Bonus issue in the proportion of 1 new equity share for every 1 (One) existing fully paid equity shares. |
| 2015-01-30 | Quarterly Results & Interim Dividend | Second Interim Dividend |
| 2014-11-14 | Quarterly Results & Interim Dividend | |
| 2014-08-08 | Quarterly Results | |
| 2014-04-30 | Audited Results & Final Dividend | |
| 2014-01-31 | Quarterly Results & 2nd Interim Dividend | |
| 2013-11-14 | Quarterly Results & Interim Dividend | |
| 2013-08-02 | Quarterly Results | |
| 2013-05-16 | Audited Results & Final Dividend | |
| 2013-02-06 | Quarterly Results & Interim Dividend | |
| 2012-10-31 | Quarterly Results & Interim Dividend | |
| 2012-08-10 | Quarterly Results | |
| 2012-07-09 | Audited Results | Inter alia, to reconsider, approve and take on record the Audited Financial Results for the year ended March 31, 2012, post amalgamation of Suyash Laboratories Ltd. with the Company. |
| 2012-05-25 | Audited Results & Final Dividend | |
| 2012-02-09 | Others | The Board has consider the Sucession Plan post retirement of Shri. Chandrakant V Gogri as the Chairman of the Company w.e.f August 16, 2012 on his attaining the age of 66 years. |
| 2012-02-01 | Quarterly Results & Interim Dividend | |
| 2011-11-11 | Quarterly Results | |
| 2011-07-29 | Quarterly Results | |
| 2011-05-25 | Audited Results & Final Dividend | |
| 2011-02-02 | Quarterly Results & Interim Dividend | |
| 2010-10-29 | Quarterly Results | |
| 2010-07-30 | Quarterly Results | |
| 2010-05-26 | Audited Results & Dividend | |
| 2010-01-25 | Quarterly Results | |
| 2009-12-20 | Allotment of Equity Shares | The Board has allotted 4,00,000 Equity Shares of Rs. 10/- each fully paid up against exercise of option of Conversion by the holders of Conv. Warrants issued by the Company on preferential basis. |
| 2009-10-30 | Quarterly Results | |
| 2009-07-30 | Quarterly Results | |
| 2009-05-20 | Audited Results & Dividend | |
| 2009-01-29 | Quarterly Results | (Revised) |
| 2008-10-20 | Quarterly Results | |
| 2008-08-06 | To call an EGM & Others | To consider: Allotment of one Equity share of Rs 10/- each & to determine "Relevant Date" for the purpose said issue price for the Preferential Issue of the warrants. |
| 2008-07-28 | Quarterly Results | |
| 2008-05-13 | Audited Results & Final Dividend | |
| 2008-01-28 | Quarterly Results | |
| 2007-10-30 | Quarterly Results | |
| 2007-07-30 | Quarterly Results | |
| 2007-05-18 | Audited Results & Final Dividend | Has not recommended any final dividend. |
| 2007-03-12 | Interim Dividend | |
| 2007-01-22 | Quarterly Results | |
| 2006-10-19 | Quarterly Results | |
| 2006-07-31 | Quarterly Results | |
| 2006-05-10 | Accounts & Dividend | |
| 2006-01-27 | Quarterly Results | |
| 2005-11-08 | Quarterly Results & Half Yearly Results | |
| 2005-07-29 | Quarterly Results & Accounts | (Revised) |
| 2005-05-05 | Others | Board has decided to acquire controlling stake in Suyash Laboratories Ltd (Suyash) thereby making it 51% subsidiary of the Company subject to necessary approvals from appropriate authority. |
| 2005-04-25 | Accounts, Qtr Results & F. Dividend | |
| 2005-04-08 | Allotment of Unsecured FCCB's | Board has allotted 12750 Unsecured Foreign Currency Convertible Bonds (FCCBs) of US$ 1000 each aggregating to US$ 12,750,000 (US Dollar Twelve Million Seven Hundred Fifty Thousand Only). |
| 2005-01-21 | Quarterly Results | |
| 2004-12-31 | To issue securities like FCCB's | Proposal to issue/offer securities like Foreign Currency Convertible Bonds (FCCB) and/or Equity Shares (through Depository Receipt Mechanism) and/or Fully Convertible Debentures. |
| 2004-10-29 | Quarterly Results | |
| 2004-07-28 | Accounts | |
| 2004-04-23 | Accounts & Final Dividend | |
| 2004-01-21 | Quarterly Results | |
| 2003-10-31 | Interim Dividend & Quarterly Results | (Revised) |
| 2003-07-21 | Quarterly Results | |
| 2003-04-23 | Final Dividend & Accounts | |
| 2003-01-20 | Quarterly Results | |
| 2002-10-28 | Accounts & Buy Back of Shares | |
| 2002-07-19 | Quarterly Results | |
| 2002-05-10 | Final Dividend | |
| 2002-04-17 | Dividend & Quarterly Results | |
| 2002-03-09 | Interim Dividend | (Cancelled) |
| 2002-01-18 | Quarterly Results | |
| 2001-10-31 | Interim Dividend & Half Yearly Results | |
| 2001-07-18 | Quarterly Results | |
| 2001-04-18 | Accounts & Dividend | Dividend announced on 11/04/2001 |
| 2001-01-22 | Quarterly Results | |
| 2000-10-18 | Quarterly Results | |
| 2000-04-18 | Accounts | |
| 2000-03-28 | 2nd Interim Dividend | |
| 2000-01-28 | Quarterly Results | |
| 1999-10-27 | Quarterly Results | |
| 1999-07-30 | Quarterly Results | |
| 1999-04-29 | Quarterly Results | |
| 1999-01-29 | Quarterly Results | |
| 1999-01-22 | Revised | |
| 1999-01-20 | Quarterly Results | |
| 1998-10-30 | Quarterly Results | |
| 1998-07-20 | Quaterly Results | |
| 1998-05-05 | Accounts & Dividend | |
| 1997-11-26 | Half Yearly Results |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 2026-02-09 | 2 | INTERIM | 2026-02-09 | Equity Share |
| 2025-02-04 | 1 | INTERIM | 2025-02-04 | Equity Share |
| 2024-02-06 | 1 | INTERIM | 2024-02-06 | Equity Share |
| 2023-02-08 | 1 | INTERIM | 2023-02-08 | Equity Share |
| 2022-02-09 | 1 | INTERIM | 2022-02-10 | Equity Share |
| 2020-11-03 | 2.5 | INTERIM | 2020-11-04 | Equity Share |
| 2020-02-17 | 2 | INTERIM | 2020-02-18 | Equity Share |
| 2019-07-26 | 1 | FINAL | Equity Share | |
| 2018-08-01 | 1 | FINAL | Equity Share | |
| 2017-08-09 | 1 | FINAL | Equity Share | |
| 2016-03-22 | 3 | INTERIM | 2016-03-24 | Equity Share |
| 2016-02-12 | 1.5 | INTERIM | 2016-02-15 | Equity Share |
| 2015-11-10 | 2.25 | INTERIM | 2015-11-14 | Equity Share |
| 2015-08-05 | 3 | FINAL | Equity Share | |
| 2015-02-04 | 5 | INTERIM | 2015-02-05 | Equity Share |
| 2014-11-19 | 5 | INTERIM | 2014-11-20 | Equity Share |
| 2014-07-02 | 5.5 | FINAL | Equity Share | |
| 2014-02-05 | 4.5 | INTERIM | 2014-02-06 | Equity Share |
| 2013-11-19 | 3 | INTERIM | 2013-11-20 | Equity Share |
| 2013-07-24 | 4 | FINAL | Equity Share | |
| 2013-02-11 | 3 | INTERIM | 2013-02-12 | Equity Share |
| 2012-11-05 | 3 | INTERIM | 2012-11-06 | Equity Share |
| 2012-08-17 | 3 | FINAL | Equity Share | |
| 2012-02-06 | 2 | INTERIM | 2012-02-07 | Equity Share |
| 2011-07-14 | 2.5 | FINAL | Equity Share | |
| 2011-02-07 | 2.5 | INTERIM | 2011-02-08 | Equity Share |
| 2010-08-18 | 5 | FINAL | Equity Share | |
| 2009-07-23 | 3 | FINAL | Equity Share | |
| 2008-08-13 | 1.8 | FINAL | Equity Share | |
| 2007-03-20 | 1.2 | INTERIM | 2007-03-21 | Equity Share |
| 2006-07-19 | 1.5 | FINAL | Equity Share | |
| 2005-07-27 | 1.6 | FINAL | Equity Share | |
| 2004-11-04 | 1.4 | INTERIM | 2004-11-06 | Equity Share |
| 2004-06-25 | 1.8 | FINAL | Equity Share | |
| 2003-11-13 | 1.2 | INTERIM | 2003-11-15 | Equity Share |
| 2003-07-25 | 1.5 | FINAL | Equity Share |
| Event Date | Event |
|---|---|
| Sep 30, 2020 | Bonus |
| Mar 24, 2015 | Bonus |
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Graviton Research Capital Llp | Bulk | 2025-05-07 |
Purchase |
393.10 | 803,477 | NSE |
| Graviton Research Capital Llp | Bulk | 2025-05-07 |
Sell |
393.62 | 803,687 | NSE |
| Blend Fund 2 | Bulk | 2024-05-28 |
Purchase |
484.97 | 511,571 | NSE |
| Mirik Rajendra Gogri | Bulk | 2024-05-28 |
Sell |
485.50 | 468,378 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-10-18 |
Purchase |
554.17 | 480,077 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-10-18 |
Sell |
554.70 | 480,077 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-07-25 |
Purchase |
627.89 | 933,060 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-07-25 |
Sell |
628.40 | 933,060 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-07-24 |
Purchase |
575.88 | 643,754 | NSE |
| Nk Securities Research Private Limited | Bulk | 2023-07-24 |
Purchase |
588.25 | 553,535 | NSE |
| Qe Securities | Bulk | 2023-07-24 |
Purchase |
587.77 | 497,273 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-07-24 |
Sell |
576.46 | 643,754 | NSE |
| Nk Securities Research Private Limited | Bulk | 2023-07-24 |
Sell |
588.59 | 553,535 | NSE |
| Qe Securities | Bulk | 2023-07-24 |
Sell |
587.73 | 505,851 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-03-24 |
Purchase |
395.14 | 723,086 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-03-24 |
Sell |
395.54 | 723,086 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-03-21 |
Purchase |
380.84 | 1,074,896 | NSE |
| Qe Securities | Bulk | 2023-03-21 |
Purchase |
382.17 | 528,794 | NSE |
| Graviton Research Capital Llp | Bulk | 2023-03-21 |
Sell |
381.00 | 1,074,896 | NSE |
| Qe Securities | Bulk | 2023-03-21 |
Sell |
382.64 | 529,570 | NSE |
| Vaibhav Stock And Derivatives Broking Private Limited | Bulk | 2021-05-06 |
Purchase |
802.99 | 563,973 | NSE |
| Vaibhav Stock And Derivatives Broking Private Limited | Bulk | 2021-05-06 |
Sell |
803.33 | 563,973 | NSE |
| Vaibhav Stock And Derivatives Broking Private Limited | Bulk | 2021-03-19 |
Purchase |
753.70 | 487,946 | NSE |
| Vaibhav Stock And Derivatives Broking Private Limited | Bulk | 2021-03-19 |
Sell |
754.04 | 487,946 | NSE |
| Xtx Markets Llp | Bulk | 2020-10-29 |
Purchase |
651.25 | 498,848 | NSE |
| Xtx Markets Llp | Bulk | 2020-10-29 |
Sell |
650.61 | 492,791 | NSE |
| N.K.Securities | Bulk | 2020-08-20 |
Purchase |
2,724.34 | 131,190 | NSE |
| N.K.Securities | Bulk | 2020-08-20 |
Sell |
2,726.39 | 131,254 | NSE |
| Aarti Surfactants Limited | Bulk | 2019-08-22 |
Sell |
446.36 | 175,000 | NSE |
| Bhavna Shantilal Shah | Bulk | 2015-01-13 |
Sell |
1,020.17 | 85,482 | NSE |
| Smp Securities Ltd. | Bulk | 2014-05-05 |
Purchase |
440.15 | 71,862 | NSE |
| Smp Securities Ltd. | Bulk | 2014-05-05 |
Sell |
437.88 | 71,862 | NSE |
| Aarti Industries Ltd | Bulk | 2014-02-18 |
Sell |
198.15 | 100,000 | NSE |
| Aarti Industries Ltd | Bulk | 2014-01-17 |
Sell |
201.21 | 100,000 | NSE |
| Kotak Mahindra (Uk)Limited A/C Premier Investment Fund Ltd | Bulk | 2013-10-10 |
Sell |
185.04 | 64,947 | NSE |
| Aarti Industries Ltd | Bulk | 2013-09-27 |
Sell |
171.01 | 150,000 | NSE |
| Anushakti Holdings Ltd | Bulk | 2013-04-18 |
Sell |
160.50 | 62,372 | NSE |
| Gogri And Sons Investments Pvt.Ltd | Bulk | 2010-12-29 |
Purchase |
140.64 | 100,000 | NSE |
| Alchemie Leasing &Amp; Financing Pvt Ltd | Bulk | 2010-12-29 |
Purchase |
140.69 | 100,000 | NSE |
| Aarti Industries Ltd | Bulk | 2010-12-29 |
Sell |
140.66 | 200,000 | NSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| Dilesh Roadlines Pvt Ltd & Others | Promoter |
Disposal |
2026-07-14 | 2,265,795 | 49,681,228 | SAST 29(2) | Market | |
| Dsp Trustee Pvt Ltd & Others | Other |
Acquisition |
2025-04-16 | 19,575 | 6,422,463 | SAST 29(2) | Market | |
| Rajendra Vallabhaji Gogri & Others | Promoter |
Disposal |
2024-06-03 | 1,838,118 | 51,206,711 | SAST 29(2) | Market | |
| Seema Harshit Savla & Others | Promoter |
Disposal |
2024-01-09 | 1,708,337 | 53,044,829 | SAST 29(2) | Market | |
| Mirik Rajendra Gogri & Others | Promoter |
Acquisition |
2023-07-06 | 40,807,929 | SAST 29(2) | Market | ||
| Mirik Rajendra Gogri & Others | Promoter |
Acquisition |
2023-06-27 | 40,807,929 | SAST 29(2) | Market | ||
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2022-01-02 | 10,000 | 1,222,662 | 524.06 | Insider Trading | Market Sale |
| Arun Moreshwar Patil | Promoter Group |
Acquisition |
2022-03-08 | 609 | 70,000 | 459.35 | Insider Trading | Market Purchase |
| Uday Moreshwar Patil | Promoter Group |
Acquisition |
2022-03-03 | 500 | 50,922 | 459.71 | Insider Trading | Market Purchase |
| Uday Moreshwar Patil | Promoter Group |
Acquisition |
2022-03-03 | 500 | 50,422 | 520.98 | Insider Trading | Market Purchase |
| Uday Moreshwar Patil | Promoter Group |
Acquisition |
2022-03-03 | 500 | 49,922 | 517.71 | Insider Trading | Market Purchase |
| Uday Moreshwar Patil | Promoter Group |
Acquisition |
2022-03-03 | 20 | 49,422 | 520.60 | Insider Trading | Market Purchase |
| Prakash Moreshwar Patil | Promoter & Director |
Acquisition |
2022-02-18 | 8,600 | 8,469,729 | 503.08 | Insider Trading | Market Purchase |
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2021-12-30 | 71,258 | 1,232,662 | 524.54 | Insider Trading | Market Sale |
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2021-12-29 | 13,120 | 1,303,920 | 526.43 | Insider Trading | Market Sale |
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2021-12-27 | 45,000 | 1,317,040 | 523.13 | Insider Trading | Market Sale |
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2021-12-27 | 8,705 | 1,362,040 | 522.21 | Insider Trading | Market Sale |
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2021-12-27 | 1,917 | 1,370,745 | 522.91 | Insider Trading | Market Sale |
| Prakash Moreshwar Patil | Promoter & Director |
Acquisition |
2021-12-27 | 200 | 8,461,129 | 517.58 | Insider Trading | Market Purchase |
| Safechem Enterprises Private Limited | Promoter Group |
Disposal |
2021-10-04 | 19,647 | 1,372,662 | 605.09 | Insider Trading | Market Sale |
About Aarti Drugs Ltd
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Aarti Drugs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 5,768.98 crores, it is incorporated in the year 1984. It features consolidated sales of Rs. 579.95 crores in June 2021. It is also listed in the Bombay Stock Exchange (BSE) with the code 524348 and listed in the National Stock Exchange (NSE) with the code AARTIDRUGS.
Aarti Drugs Ltd was incorporated as a private limited company on 28th September ’1984 and converted into a public limited company in 1992. It is owned by Aarti Industries Ltd, which also owns a Research & Development plant in Tarapur, Maharashtra. The Company is engaged in manufacturing Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly-owned subsidiary – Pinnacle Life Science Private Limited. The Company operates through eight manufacturing facilities, two of which are strategically located in the state of Gujarat and Maharashtra. Also, all the manufacturing units of Aarti Industries are GMP certified, and therefore, the Company is additionally in the process of acquiring certification as per ISO 9002 compliance standard for all its units, out of which one has received the certification. The promoters of the Company currently hold 60.14% of the stake in the Company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 2.57% and 2% of the stake. The balance of 35.29% is held by others (retail investors).
In June 2021, quarterly net sales were Rs. 505.79 crores, which has increased by approximately 6.36% from Rs. 475.55 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 45.54 crores, which has fallen by 37.64% from a net profit of Rs. 73.03 crores in June 2020. In June 2021, the operating profit was Rs. 429.79 crores, which is also increased by 3.51% as compared to the operating profit of Rs. 415.22 crores for the quarter ending in June 2020. From Rs. 31.34 in June 2020, the EPS of Aarti Drugs has been reduced to just Rs. 4.9 per share in June 2021. AARTIDRUGS’s stock closed at Rs. 634.80 on 16th August’2021 (NSE) and has returned -1.50% in the last six months and -70.23% in the last year.
Aarti Drugs share price as on 21 Sep 2026 is Rs. 431.8. Over the past 6 months, the Aarti Drugs share price has increased by 29.22% and in the last one year, it has decreased by 16.2%. The 52-week low for Aarti Drugs share price was Rs. 318.95 and 52-week high was Rs. 534.
Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal, Thane, Maharashtra, 401506
Tel No. 91-22-24072249
Email investorrelations:aartidrugs.com
Independent Non Exe. Director
Independent Non Exe. Director
Company Sec. & Compli. Officer
CMD & Executive Director
Independent Non Exe. Director
ED / MD / Promoter
Independent Non Exe. Director
WTD & Executive Director
Independent Non Exe. Director
ED / Joint MD / Promoter
Non Executive Director
E D & Wholetime Director
Independent Non Exe. Director
Chairman Emeritus
524348
AARTIDRUGS
INE767A01016
Sep
Aarti Drugs Ltd FAQs
You can buy Aarti Drugs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aarti Drugs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 18, 2026 03:57 PM the closing price of Aarti Drugs Ltd was Rs.431.80.
The latest PE ratio of Aarti Drugs Ltd as of Sep 18, 2026 03:57 PM is 20.62
The latest PB ratio of Aarti Drugs Ltd as of Sep 18, 2026 03:57 PM is 2.54
The 52-week high of Aarti Drugs Ltd share price is Rs. 534.00 while the 52-week low is Rs. 318.95
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 18, 2026 03:57 PM, the market cap of Aarti Drugs Ltd stood at Rs. 3,941.04 Cr.
